Equities Analysts Issue Forecasts for ResMed Q3 Earnings

ResMed Inc. (NYSE:RMD) – Equities research analysts at William Blair raised their Q3 2025 earnings per share (EPS) estimates for shares of ResMed in a note issued to investors on Friday, December 6th. William Blair analyst M. Andrew now anticipates that the medical equipment provider will post earnings per share of $2.37 for the quarter, up from their previous forecast of $2.33. The consensus estimate for ResMed’s current full-year earnings is $9.34 per share. William Blair also issued estimates for ResMed’s Q4 2025 earnings at $2.44 EPS and FY2025 earnings at $9.30 EPS.

ResMed (NYSE:RMD) last posted its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share for the quarter, topping the consensus estimate of $2.03 by $0.17. ResMed had a return on equity of 25.53% and a net margin of 23.15%. The firm had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.19 billion. During the same period last year, the company posted $1.64 EPS. The business’s quarterly revenue was up 11.1% on a year-over-year basis.

Several other research analysts have also weighed in on the company. StockNews.com raised ResMed from a “hold” rating to a “buy” rating in a research report on Tuesday, October 15th. Bank of America lifted their price objective on ResMed from $240.00 to $270.00 and gave the stock a “buy” rating in a research report on Thursday, September 26th. Baird R W raised ResMed to a “strong-buy” rating in a research report on Tuesday, September 24th. KeyCorp lifted their price objective on ResMed from $251.00 to $266.00 and gave the stock an “overweight” rating in a research report on Friday, October 25th. Finally, Needham & Company LLC restated a “hold” rating on shares of ResMed in a research note on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, ResMed currently has a consensus rating of “Moderate Buy” and an average target price of $225.70.

ResMed Stock Performance

RMD stock opened at $245.22 on Monday. The stock has a 50-day moving average price of $242.31 and a 200-day moving average price of $226.81. ResMed has a 1-year low of $162.18 and a 1-year high of $260.49. The company has a current ratio of 2.92, a quick ratio of 1.91 and a debt-to-equity ratio of 0.13. The firm has a market cap of $36.00 billion, a PE ratio of 32.48, a price-to-earnings-growth ratio of 1.75 and a beta of 0.68.

ResMed Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 12th. Shareholders of record on Thursday, November 7th will be paid a dividend of $0.53 per share. The ex-dividend date of this dividend is Thursday, November 7th. This represents a $2.12 dividend on an annualized basis and a yield of 0.86%. ResMed’s dividend payout ratio (DPR) is currently 28.08%.

Insider Buying and Selling at ResMed

In other ResMed news, insider Justin Leong sold 6,160 shares of ResMed stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $243.09, for a total transaction of $1,497,434.40. Following the completion of the transaction, the insider now owns 21,718 shares in the company, valued at approximately $5,279,428.62. The trade was a 22.10 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Peter C. Farrell sold 2,000 shares of ResMed stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $245.65, for a total value of $491,300.00. Following the transaction, the director now owns 81,218 shares of the company’s stock, valued at $19,951,201.70. This trade represents a 2.40 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 52,725 shares of company stock worth $12,516,248. Insiders own 0.71% of the company’s stock.

Hedge Funds Weigh In On ResMed

A number of hedge funds and other institutional investors have recently modified their holdings of RMD. True Wealth Design LLC boosted its stake in shares of ResMed by 2,200.0% in the 3rd quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 110 shares during the last quarter. OFI Invest Asset Management purchased a new position in shares of ResMed in the 2nd quarter worth approximately $32,000. Ashton Thomas Securities LLC purchased a new position in shares of ResMed in the 3rd quarter worth approximately $34,000. Financial Connections Group Inc. purchased a new position in shares of ResMed in the 2nd quarter worth approximately $37,000. Finally, Blue Trust Inc. boosted its stake in shares of ResMed by 182.7% in the 2nd quarter. Blue Trust Inc. now owns 212 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 137 shares during the last quarter. Hedge funds and other institutional investors own 54.98% of the company’s stock.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.